Esculentoside A

Esculentoside A (EsA), a kind of triterpene saponin isolated from roots of Phytolacca esculenta[1]. Esculentoside A (EsA) possesses anti-inflammatory activity in acute and chronic experimental models[2], has selective inhibitory activity towards cyclooxygenase-2 (COX-2) [1]. Esculentoside A (EsA) suppresses inflammatory responses in LPS-induced acute lung injury (ALI) through inhibition of the nuclear factor kappa B (NF-ΚB) and mitogen activated protein kinase (MAPK) signaling pathways[3].

Product Specifications

CAS Number

[65497-07-6]

UNSPSC

12352005

Hazard Statement

H302

Target

COX; NF-κB

Type

Natural Products

Related Pathways

Immunology/Inflammation; NF-κB

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/esculentoside-a.html

Concentration

10mM

Purity

99.89

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

C[C@@]1(CC[C@]2(C(O)=O)[C@@]3([H])C[C@](C(OC)=O)(C)CC2)C3=CC[C@@]4([H])[C@]1(CC[C@]5([H])[C@@]4(C[C@H](O)[C@H](O[C@@](OC[C@@H](O[C@]([C@@H]([C@@H](O)[C@@H]6O)O)([H])O[C@@H]6CO)[C@@H]7O)([H])[C@@H]7O)[C@@]5(C)CO)C)C

Molecular Formula

C42H66O16

Molecular Weight

826.96

Precautions

H302

References & Citations

[1]Wu F, et al. Synthesis, in vitro inhibitory activity towards COX-2 and haemolytic activity of derivatives of esculentoside A. Bioorg Med Chem Lett. 2007 Dec 1;17 (23) :6430-3. Epub 2007 Oct 5.|[2]Ma H, et al. The effect of esculentoside A on lupus nephritis-prone BXSB mice. Arch Med Sci. 2013 Apr 20;9 (2) :354-60.|[3]Zhong WT, et al. Protective effect of esculentoside A on lipopolysaccharide-induced acute lung injury in mice. J Surg Res. 2013 Nov;185 (1) :364-72.|[4]Ju DW, et al. Esculentoside A inhibits tumor necrosis factor, interleukin-1, and interleukin-6 production induced by lipopolysaccharide in mice. Pharmacology. 1998 Apr;56 (4) :187-95|[5]Zhong WT, et al. Protective effect of esculentoside A on lipopolysaccharide-induced acute lung injury in mice. J Surg Res. 2013 Nov;185 (1) :364-72.